

A combination of variant genotypes at two loci in the *APOL1* gene is associated with adverse outcomes in SARS-CoV-2: a UK Biobank study.

Walt Adamson¹, Harry Noyes², Georgia Beckett-Hill¹, Anneli Cooper¹, and Annette MacLeod¹

Author information:

1. Institute of Biodiversity, Animal Health, and Comparative Medicine, University of Glasgow, Glasgow, UK.
2. Institute of Integrative Biology, University of Liverpool, Liverpool, UK.

For correspondence: annette.macleod@glasgow.ac.uk

Abstract

The risk of hospitalisation or death from Covid-19 in the UK is disproportionately higher in black ethnic populations than others for reasons that are not fully understood¹. In people of African ancestry, variants of the *APOL1* gene (G1 and G2) have been associated with risk of a number of non-communicable diseases, such as chronic kidney disease^{2,3,4,5} and the infectious disease, African sleeping sickness⁶. Here we test the hypothesis that adverse Covid-19 outcomes are also associated with these variants.

Using data from Black UK Biobank participants, we used Firth's Bias-Reduced Logistic Regression in R to identify *APOL1* genotypes that were associated with either hospitalisation or death. *APOL1* G1/G2 compound heterozygotes were associated with hospitalisation (OR = 2.4 95% CI: 1.2-4.5) $p = 0.010$ and death (OR = 5.4, 95% CI: 1.8-15.4, $p = 0.004$) compared to individuals not carrying the variants. This supports hypotheses proposing *APOL1* genotype (specifically G1/G2) is a significant contributory factor in the increased rates of poor Covid-19 outcomes observed in people of African ancestry. This has implications for both at the individual and population level by identifying those at higher risk of severe Covid-19 who would benefit from early vaccination and treatment. This is especially relevant to geographical regions where *APOL1* G1/G2 genotypes are common such as West and Central Africa⁶ and their diaspora.

A combination of variant genotypes at two loci in the APOL1 gene is associated with adverse outcomes in SARS-CoV-2: a UK Biobank study.

Walt Adamson, Harry Noyes, Georgia Beckett-Hill, Anneli Cooper, and Annette MacLeod

The risk of hospitalisation or death from Covid-19 in the UK is disproportionately higher in black ethnic populations than others for reasons that are not fully understood¹. In people of African ancestry, variants of the *APOL1* gene have been associated with risk of a number of non-communicable diseases such as chronic kidney disease^{2,3,4,5}. Here we test the hypothesis that adverse Covid-19 outcomes are also associated with these variants.

Within the last 10,000 years two variants of the *APOL1* gene have arisen in the African population, termed G1 (encoding S342G and I384M) and G2 (encoding deletion of N388 and Y389), which are present on different haplotypes and are absent or at very low frequency in non-African derived populations². Individuals who have neither variant are termed G0/G0. As well as being associated with a number of non-communicable diseases, G1 and G2 are associated with alternate outcomes from the infectious disease African sleeping sickness, which is caused by two subspecies of *T. brucei*, *T.b. gambiense* and *T.b. rhodesiense*⁶. G1 is associated with milder *T.b. gambiense* infection, whereas G2 is associated with more severe *T.b. gambiense* disease, yet protection from *T.b. rhodesiense* infection⁶. In G1/G2 compound heterozygotes, G1 mitigates the risk associated with G2 *gambiense* disease severity⁶. Since the effect of *APOL1* genotype on infection by SARS-CoV-2 could not be predicted based on our current knowledge, we tested the six variant combinations that have been detected in African populations.

We used data from the UK Biobank, a large-scale biomedical database and research resource containing genetic, lifestyle, and health information from half a million UK participants from across the UK⁷. The UK Biobank includes 7,643 individuals who self-report as being of black ethnicity, including 7,600 who have unambiguous genotype data for *APOL1* variants. Within this cohort there have been 142 hospitalisations and 36 deaths attributed to Covid-19 as of September 2021 (Table 1). Taking the four most significant UK Biobank principal components as covariates along with risk factors previously associated with Covid-19 (age, sex, chronic kidney disease (CKD), atrial fibrillation, hypertension, depression, chronic obstructive pulmonary disease (COPD), dementia, type 2 diabetes⁸, obesity⁹ and Townsend deprivation index¹⁰), we used Firth's Bias-Reduced Logistic Regression in R to identify *APOL1* genotypes that were associated with either hospitalisation or death. G1/G2 compound heterozygotes were associated with hospitalisation (OR = 2.4 95% CI: 1.2-4.5) $p = 0.010$ and death (OR = 5.4, 95% CI: 1.8-15.4, $p = 0.004$) compared to G0/G0 (Table 1). This association has not been previously detected in genome wide association studies^{11,12} as they usually examine individual loci separately rather than consider combinations of loci.

Black UK Biobank participants who have been hospitalised and/or died as a result of SARS-CoV-2 infection represent a relatively small dataset, and verification in a larger cohort is required. However, our observations support hypotheses proposing *APOL1* genotype (specifically G1/G2 compound heterozygotes) as a significant contributory factor in the increased rates of poor Covid-19 outcomes observed in people of African ancestry. Indeed, there are anecdotal reports of that *APOL1* genotypes may be associated with severe collapsing glomerular nephropathy in SARS-CoV-2 infection¹³ and G1/G2 compound heterozygotes have been shown to be associated with HIV-associated nephropathy¹⁴. The molecular mechanism behind the association of G1/G2 and deleterious SARS-CoV-2 infection outcome is unclear but warrants further investigation. This association could have important implications both at the individual and population level by identifying those at higher risk of severe Covid-19 who would benefit from early vaccination and treatment. This is especially relevant to geographical regions where *APOL1* G1/G2 genotypes are common such as West and Central Africa⁶ and their diaspora.

Risk Factor	N	Hospitalised N (%)	Hospitalised OR (95% CI)	Hospitalised P	Death N (%)	Death OR (95% CI)	Death P
G0/G1	2274	46 (2.02%)	1.2 (0.8-1.8)	0.481	10 (0.44%)	1.3 (0.5-3.2)	0.584
G0/G2	1185	17 (1.43%)	0.8 (0.4-1.4)	0.443	4 (0.34%)	1.0 (0.3-2.8)	0.970
G1/G1	711	11 (1.55%)	0.9 (0.4-1.6)	0.639	2 (0.28%)	1.1 (0.2-3.9)	0.911
G1/G2	313	13 (4.15%)	2.4 (1.2-4.5)	0.010	6 (1.92%)	5.4 (1.8-15.4)	0.004
G2/G2	131	2 (1.53%)	1.3 (0.3-4.0)	0.689	1 (0.76%)	4.2 (0.4-19.6)	0.173

Table 1: Risk of hospitalisation or death due to Covid-19 of black participants in the UK Biobank, comparing different APOL1 genotypes to G0/G0, adjusted for age group (the cohort was divided into six equal groups), sex, body mass index > 30 (Obesity), diagnosis of: chronic kidney disease (CKD), atrial fibrillation, hypertension, depression, chronic obstructive pulmonary disease (COPD), dementia, type 2 diabetes and the top 4 most significant UK Biobank genetic principle components (PCA1, 4, 6 and 10).

References

1. Mathur R., Rentsch CT., Morton CE., *et al.* (2021). Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. *The Lancet*, [https://doi.org/10.1016/S0140-6736\(21\)00634-6](https://doi.org/10.1016/S0140-6736(21)00634-6).
2. Genovese G., Friedman DJ., Ross MD., *et al.* (2010). Association of trypanolytic APOL1 variants with kidney disease in African Americans. *Science*, <https://doi.org/10.1126/science.1193032>
3. Yusuf, AA, Govender, MA., Brandenburg, JT., and Winkler, CA. (2021) Kidney disease and APOL1. *Human Molecular Genetics* <https://doi.org/10.1093/hmg/ddab024>
4. Nadkarni GN., Galarneau G., Ellis SB., *et al.* (2017). Apolipoprotein L1 variants and blood pressure traits in African Americans. *Journal of the American College of Cardiology*, <https://doi.org/10.1016/j.jacc.2017.01.040>.
5. Gutiérrez OM., Irvin MR., Zakai NA., *et al.* (2020). APOL1 nephropathy risk alleles and mortality in African American adults: a cohort study. *American Journal of Kidney Disease*, <https://doi.org/10.1053/j.ajkd.2019.05.027>.
6. Cooper A., Ilboudo H., Pius Alibu V., *et al.* (2017). APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. *eLIFE*, <http://dx.doi.org/10.7554/eLife.25461>.
7. Bycroft C., Freeman C., Petkova D., *et al.* (2018). The UK Biobank resource with deep phenotyping and genomic data. *Nature*, <https://dx.doi.org/10.1038%2Fs41586-018-0579-z>.
8. Atkins JL., Masoli JAH., Delgado J., *et al.* (2020). Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank community cohort. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, <https://dx.doi.org/10.1093%2Fgerona%2Fglaa183>. Parsa A., Kao WHL., Xie D., *et al.* (2013). APOL1 risk variants, race, and progression of chronic kidney disease. *New England Journal of Medicine*, <https://doi.org/10.1056/nejmoa1310345>. Atkins JL., Masoli JAH., Delgado J., *et al.* (2020). Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort. *The journals of gerontology. Series A, Biological sciences and medical sciences*. <https://doi.org/10.1093/gerona/glaa183>.
9. Docherty AB., Harrison EM., Green CA *et al.* (2020). Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *The British Medical Journal*, <https://doi.org/10.1136/bmj.m1985>.

10. Woodward M., Peters SAE., and Harris K. Social deprecation as a risk factor for COVID-19 mortality among women and men in the UK Biobank: nature of risk and context suggests that social interventions are essential to mitigate the effects of future pandemics. (2021). *Journal of Epidemiology and Health*, <http://dx.doi.org/10.1136/jech-2020-215810>.
11. Pairo-Castineira E., Clohisey S., Klaric L., *et al.* (2020). Genetic mechanisms of critical illness in COVID-19. *Nature*, <https://doi.org/10.1038/s41586-020-03065-y>.
12. Shelton JF., Shastri AJ., Ye C., *et al.* (2021). Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. *Nature Genetics*, <https://doi.org/10.1038/s41588-021-00854-7>.
13. Velez JCQ., Caza T., and Larsen CP. (2020). COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. *Nature Reviews Nephrology*, <https://doi.org/10.1038/s41581-020-0332-3>.
14. Kasembeli AN., Duarte R., Ramsey M., *et al.* (2015). APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. *Journal of the American Society of Nephrology*, <https://doi.org/10.1681/ASN.2014050469>.